Forward contract and derivative liability, measurement input Forward Contract and Derivative Liability, Measurement Input Forward Contract and Derivative Liability, Measurement Input Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Related Party Transactions Related Party Transactions Disclosure [Text Block] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Cover page. Cover [Abstract] Net decrease in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Discount rate Measurement Input, Discount Rate [Member] Due to related party Other Liabilities, Current Trading Symbol Trading Symbol Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Schedule of basic and diluted net loss per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Lead Asset Lead Asset [Member] Lead Asset Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Milestone payments Payments For Milestone Achievements Payments For Milestone Achievements Other Commitments [Line Items] Other Commitments [Line Items] Pay vs Performance Disclosure [Line Items] Developmental And Regulatory Milestones, Second Asset Developmental And Regulatory Milestones, Second Asset [Member] Developmental And Regulatory Milestones, Second Asset Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Prepaid Expenses Prepaid Expense, Current [Abstract] Nature of the Business and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Less than one year Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Amortized Cost Fair Value of Financial Assets and Liabilities Fair Value Disclosures [Text Block] Proceeds from equity incentive plan Proceeds from Stock Options Exercised Award Timing Disclosures [Line Items] Merus N.V. Agreement Merus N.V. Agreement [Member] Merus N.V. Agreement Other Performance Measure, Amount Other Performance Measure, Amount Common shares, outstanding (shares) Common Stock, Shares, Outstanding Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Non-current operating lease liability Operating Lease, Liability, Noncurrent Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] License and other agreements Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Realized gains and losses on sales of debt securities Debt Securities, Available-for-Sale, Realized Loss Percentage of repurchased after third anniversary Note Purchase Agreement, Purchase Price Percentage, Less than Total Funded Amount, Repurchased After Third Anniversary of Closing Date Note Purchase Agreement, Purchase Price Percentage, Less than Total Funded Amount, Repurchased After Third Anniversary of Closing Date Other non-current assets Other non-current assets Other Assets, Noncurrent Yale University Yale University [Member] Yale University Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Money market funds Money Market Funds [Member] Operating Segments Operating Segments [Member] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Proceeds from sale of stock Sale of Stock, Consideration Received on Transaction Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] U.S. treasury bills US Treasury Securities [Member] Schedule of activity in accumulated other comprehensive income (loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Project [Domain] Project [Domain] Issuance of common shares as payment for assets (in shares) Stock Issued During Period, Shares, Purchase of Assets Prepaid expenses Prepaid Expense, Current Equity Components [Axis] Equity Components [Axis] Share-Based Compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Schedule of milestone payments Schedule of Milestone Payments [Table Text Block] Schedule of Milestone Payments Other current assets Other Assets, Current Award Timing Method Award Timing Method [Text Block] Office and lab equipment Office Equipment [Member] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Fair Value Debt Securities, Available-for-Sale Measurement Frequency [Axis] Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Use of Estimates Use of Estimates, Policy [Policy Text Block] Total operating expenses Costs and Expenses Total funded amount threshold percentage Note Purchase Agreement, Purchase Price Percentage, Total Funded Amount Threshold Percentage Note Purchase Agreement, Purchase Price Percentage, Total Funded Amount Threshold Percentage Adjustment to Compensation, Amount Adjustment to Compensation Amount Aggregate intrinsic value of options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Proceeds from maturities of marketable securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Tabular List, Table Tabular List [Table Text Block] Gross investment income (including realized losses) Investment Income, Interest and Dividend Level 3 Fair Value, Inputs, Level 3 [Member] Share-Based Compensation Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Schedule of other noncurrent assets Schedule of Other Assets, Noncurrent [Table Text Block] Number of securities called by warrants (shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Accrued expenses and other current liabilities  Accrued expenses and other current liabilities Accrued Liabilities, Current Anti-dilutive securities excluded from calculation of diluted net loss per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Percentage of total funded amount, required purchase price paid after closing date Note Purchase Agreement, Purchase Price Percentage, Less than Total Funded Amount, Repurchased After Eighth Anniversary of Closing Date Note Purchase Agreement, Purchase Price Percentage, Less than Total Funded Amount, Repurchased After Eighth Anniversary of Closing Date BHV-1310 (IgG Degrader) BHV-1310 (IgG Degrader) [Member] BHV-1310 (IgG Degrader) Upfront Payments - Issuance of Common Shares Upfront Payments - Issuance of Stock Upfront Payments - Issuance of Stock Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Total cash, cash equivalents and restricted cash at the end of the period in the condensed consolidated statement of cash flows Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Total unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Current assets: Assets, Current [Abstract] Goodwill Goodwill Consolidation Items [Axis] Consolidation Items [Axis] Percentage of milestone payment obligations Note Purchase Agreement, Milestone Payment Obligation, Percentage of Funding Note Purchase Agreement, Milestone Payment Obligation, Percentage of Funding Reduction in percentage of revenue payments on net sales Note Purchase Agreement, Reduction in Percentage of Revenue Payments on Net Sales Reduction In Percentage of Revenue Payments on Net Sales Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Options to purchase common shares Share-Based Payment Arrangement, Option [Member] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Upfront Payments - Cash Upfront Payments, Cash Payments Upfront Payments, Cash Payments Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Depreciation Depreciation Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Marketable securities Marketable Securities, Current Other financing activities, net Proceeds from (Payments for) Other Financing Activities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Issuance of common shares as payment under license and other agreements (in shares) Stock Issued During Period, Shares, Collaborative Arrangement Stock Issued During Period, Shares, Collaborative Arrangement Preferred stock outstanding (share) Preferred Stock, Shares Outstanding Number of prodrugs of glutamate modulating agents Number of Prodrugs of Glutamate Modulating Agents Represents the number of prodrugs of glutamate modulating agents. Warrants to purchase common shares Warrant [Member] Security Exchange Name Security Exchange Name Schedule of available-for-sale debt securities by contractual maturity Investments Classified by Contractual Maturity Date [Table Text Block] Award Type [Axis] Award Type [Axis] Related Party Transaction [Domain] Related Party Transaction [Domain] ALS Biopharma Agreement ALS Biopharma And Fox Chase Chemical Diversity Center Inc [Member] Represents information pertaining to the entity's license agreement with ALS Biopharma and Fox Chase Chemical Diversity Center Inc (the "ALS Biopharma Agreement") to which they assigned the Company their worldwide patent rights. Issuance of common shares as payment for IPR&D asset Stock Issued During Period, Value, Purchase of Assets Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Percentage of one-time payment obligations Note Purchase Agreement, One-Time Payment Obligation Fee for Unsatisfied Test Date Condition, Percentage Note Purchase Agreement, One-Time Payment Obligation Fee for Unsatisfied Test Date Condition, Percentage Number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Total liabilities Liabilities Schedule of reconciliation of total cash, cash equivalents and restricted cash Schedule of Cash and Cash Equivalents [Table Text Block] Test date condition, satisfaction rate on total payments, equal to or greater than 90% Note Purchase Agreement, Unsatisfied Test Date Condition, Total Payments Threshold Percentage Note Purchase Agreement, Unsatisfied Test Date Condition, Total Payments Threshold Percentage Options exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Other Other Assets, Miscellaneous, Noncurrent Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development Research and Development Expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Expiration Date Trading Arrangement Expiration Date Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Upfront payment of common shares, value Acquisition, Consideration Transferred, Equity Interest Issued and Issuable Acquisition, Consideration Transferred, Equity Interest Issued and Issuable Tax on other comprehensive income (loss) Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Operating lease liabilities - current portion Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common shares, issued (shares) Common Stock, Shares, Issued Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Computer hardware and software Computer Equipment [Member] BHV-4157 (Troriluzole) BHV-4157 (Troriluzole) [Member] BHV-4157 (Troriluzole) Other non-current assets Other Assets, Fair Value Disclosure Long-Term Purchase Commitment, Category of Item Purchased [Domain] Long-Term Purchase Commitment, Category of Item Purchased [Domain] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Subsequent Events Subsequent Event [Line Items] Property and equipment, gross Property, Plant and Equipment, Gross Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Research and development expenses Research and Development Expense [Member] Issuance of common shares as payment for acquisition of IPR&D asset Issuance of Common Shares for Acquisition of Research and Development Asset Issuance of Common Shares for Acquisition of Research and Development Asset Common shares, authorized (shares) Common Stock, Shares Authorized Other Agreements Other Agreements [Member] Other Agreements Unaudited Interim Condensed Consolidated Financial Information Basis of Accounting, Policy [Policy Text Block] Common shares received (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Common Stock Receivable Upon Vesting Share-based Compensation Arrangement by Share-based Payment Award, Common Stock Receivable Upon Vesting Weighted average common shares outstanding—diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted R&D Share-based compensation expense Research And Development Expense, Share-Based Compensation Expense Research And Development Expense, Share-Based Compensation Expense MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] AOCI [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Percentage of total funded amount, required purchase price paid on or after closing date Note Purchase Agreement, Purchase Price Percentage, Less than Total Funded Amount, Repurchased Prior to Eighth Anniversary of Closing Date Note Purchase Agreement, Purchase Price Percentage, Less than Total Funded Amount, Repurchased Prior to Eighth Anniversary of Closing Date Total shareholders' equity Beginning balance Ending balance Equity, Attributable to Parent Related Party Related Party [Member] Milestone payment to be paid upon development achievement Development milestone payment to be paid Milestone Payment To Be Paid By Company Upon Specified Development Milestone Achievement Milestone Payment To Be Paid By Company Upon Specified Development Milestone Achievement BHV-1510 (Trop2) BHV-1510 (Trop2) [Member] BHV-1510 (Trop2) Forward contract and derivative liability Forward Contract and Derivative Liability, Current Forward Contract and Derivative Liability, Current Funded loan amount on, test date condition not satisfied , less than 50% Note Purchase Agreement, Cap Amount Multiplier, Unsatisfied Test Date Condition, Less than Total Funded Amount Percentage Note Purchase Agreement, Cap Amount Multiplier, Unsatisfied Test Date Condition, Less than Total Funded Amount Percentage Balance Sheet Location [Axis] Statement of Financial Position Location, Balance [Axis] Net investment income Investment Income, Net Category of Item Purchased [Axis] Category of Item Purchased [Axis] Success-based payments Acquisition, Contingent Consideration, Liability Acquisition, Contingent Consideration, Liability Other comprehensive loss Total other comprehensive loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Recurring Fair Value, Recurring [Member] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Securities excluded from computation of diluted net loss per share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Sale of Stock [Domain] Sale of Stock [Domain] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Balance Sheet Location [Domain] Statement of Financial Position Location, Balance [Domain] Net unrealized investment gains (losses): AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Weighted average remaining contractual term of options outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Assets Assets [Abstract] Other comprehensive loss, net of tax Other Comprehensive Income (Loss), Net of Tax Document Type Document Type Derivative Contract [Domain] Derivative Contract [Domain] Percentage of revenue payments on net sales Note Purchase Agreement, Percentage of Revenue Payments on Net Sales Note Purchase Agreement, Percentage of Revenue Payments on Net Sales Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Schedule of Segment Profit or Loss and Significant Segment Expenses Schedule of Segment Reporting Information, by Segment [Table Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Investment expenses Investment Income, Investment Expense Common shares issuable, value (in shares) Forward Contract, Obligation for Stock Issuable, Shares Forward Contract, Obligation for Stock Issuable, Shares Weighted average remaining contractual term of options exercisable (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Commercial Sales-Based Milestones Commercial Sales-Based Milestones [Member] Commercial Sales-Based Milestones Total Shareholders' Equity Parent [Member] Subsequent Event [Table] Subsequent Event [Table] Common shares, par value (in dollars per share) Common Stock, No Par Value Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Project [Axis] Project [Axis] Furniture and fixtures Furniture and Fixtures [Member] Milestone payment to be paid upon regulatory achievement Milestone Payment to be Paid by Company Upon Specified Regulatory Milestone Achievement Represents the amount of milestone payment to be paid by the company upon the achievement of specified regulatory milestones and annual royalty payments based on net sales of products from patents. Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Leasehold improvements Leasehold Improvements [Member] Current Fiscal Year End Date Current Fiscal Year End Date Preclinical research programs R&D Expense Research And Development, Preclinical Research Programs Research And Development, Preclinical Research Programs Less than one year Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] Name Outstanding Recovery, Individual Name Research commitments Long-Term Purchase Commitment, Amount Issuance of common shares under equity incentive plan (shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Schedule of potentially anti-dilutive securities excluded from calculation of diluted net loss per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Forward Contract Liability, 2025 Addtional Consideration Forward Contract Liability, 2025 Addtional Consideration [Member] Forward Contract Liability, 2025 Addtional Consideration Marketable securities Investments, Fair Value Disclosure Other comprehensive income (loss) before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent Additional Paid-in Capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Collaborative arrangement Collaborative Arrangement [Member] Percentage of voluntary repurchase Note Purchase Agreement, Purchase Price Percentage, Change of Control or Voluntary Repurchase Note Purchase Agreement, Purchase Price Percentage, Change of Control or Voluntary Repurchase Restricted cash (included in other non-current assets) Restricted Cash, Noncurrent Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Yale MoDE Agreement Yale MoDE Agreement [Member] Yale MoDE Agreement Net loss per share — diluted (in dollars per share) Net loss per share - diluted (in dollars per share) Earnings Per Share, Diluted Counterparty Name [Domain] Counterparty Name [Domain] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Proceeds from the sale of available-for-sale debt securities Proceeds from Sale of Debt Securities, Available-for-Sale Weighted average remaining contractual term of options vested and expected to vest (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Acquisition [Domain] Acquisition [Domain] Acquisition [Domain] Preferred stock issued (share) Preferred Stock, Shares Issued Amount of funding Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments Schedule of financial assets and liabilities measured at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Number of claims Number of Claims of Patents to Reassign Represents the number of claims if the Company abandons the sale of all products that will cause the reassignment of the applicable patent rights back to ALS Biopharma. Non-cash share-based compensation Total non-cash share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Fair value of RSUs vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Reportable Segment Reportable Segment [Member] Reportable Segment Provision for income taxes Provision for income taxes Income Tax Expense (Benefit) Warrants, fair value disclosure Warrants, Fair Value Disclosure Warrants, Fair Value Disclosure Forward Contract and Derivative Liabilities Forward Contract and Derivative Liabilities [Member] Forward Contract and Derivative Liabilities Weighted average period for recognition of compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Developmental And Regulatory Milestones, First Asset Developmental And Regulatory Milestones, First Asset [Member] Developmental And Regulatory Milestones, First Asset Other income, net Nonoperating Income (Expense) Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Loss from operations Operating Income (Loss) Research and development Research and Development Expense (Excluding Acquired in Process Cost) License, Acquisitions and Other Agreements License, Acquisitions and Other Agreements [Text Block] License, Acquisitions and Other Agreements Total liabilities and shareholders' equity Liabilities and Equity Subsequent Events Subsequent Events [Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Accrued employee compensation and benefits Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Prepaid expenses and other current and non-current assets Increase (Decrease) in Prepaid Expense and Other Assets Additional paid-in capital Additional Paid in Capital Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Funded loan amount on, test date condition not satisfied Note Purchase Agreement, Cap Amount Multiplier, Unsatisfied Test Date Condition Note Purchase Agreement, Cap Amount Multiplier, Unsatisfied Test Date Condition Underlying Security Market Price Change Underlying Security Market Price Change, Percent Equity Distribution Agreement Equity Distribution Agreement [Member] Equity Distribution Agreement Measurement Input Type [Axis] Measurement Input Type [Axis] Individual: Individual [Axis] Related Party Transaction [Axis] Related Party Transaction [Axis] Accumulated Other Comprehensive Income (Loss) Accumulated other comprehensive income AOCI Attributable to Parent [Member] First Notes First Notes [Member] First Notes G&A Share-based compensation expense General And Administrative Expense, Share-Based Compensation General And Administrative Expense, Share-Based Compensation Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price BHV-1300 (IgG Degrader) BHV-1300 (IgG Degrader) [Member] BHV-1300 (IgG Degrader) Entity Address, State or Province Entity Address, State or Province Statement [Line Items] Statement [Line Items] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Highlightll Pharmaceutical Co, Ltd. Highlightll Pharmaceutical Co, Ltd. [Member] Highlightll Pharmaceutical Co, Ltd. Measurement Input Type [Domain] Measurement Input Type [Domain] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Schedule of changes in shareholders' equity (deficit) Schedule of Stockholders Equity [Table Text Block] Milestone payment to be paid upon commercial achievement Commercial milestone payment to be paid Milestone Payment to be Paid by Company Upon Specified Commercial Milestone Achievement Represents the amount of milestone payment to be paid by the company upon the achievement of specified commercial milestones and annual royalty payments based on net sales of products from patents. Operating expenses: Operating Expenses [Abstract] Net investment income Investment Income, Net [Abstract] BHV-1600 (β1-AR AAB Degrader) BHV-1600 (β1-AR AAB Degrader) [Member] BHV-1600 (β1-AR AAB Degrader) Schedule of property and equipment, net Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Unvested, beginning (in dollars per share) Unvested, ending (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and Shareholders' Equity Liabilities and Equity [Abstract] Balance at beginning of period Balance at end of period Fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Preferred stock, par value (in dollars per share) Preferred Stock, No Par Value Taldefgrobep Alfa License Agreement Taldefgrobep Alfa License Agreement [Member] Taldefgrobep Alfa License Agreement Percentage of repurchased after closing date Note Purchase Agreement, Purchase Price Percentage, Repurchased After the End of Voluntary Repurchase Period Note Purchase Agreement, Purchase Price Percentage, Repurchased After the End of Voluntary Repurchase Period Success-based milestone payments, based on regulatory approval Success-Based Milestone Payments to be Paid, Based On Regulatory Approval Success-Based Milestone Payments to be Paid, Based On Regulatory Approval Restatement Determination Date Restatement Determination Date Options vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Schedule of reconciliation of available-for-sale debt securities from amortized cost to fair value Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Outstanding at beginning of period (in dollars per share) Outstanding at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Test date condition, satisfaction rate on total payments, equal to or greater than 50%, then required purchase price percentage Note Purchase Agreement, Purchase Price Percentage, Exercise of Put Option, Greater than Total Funded Amount Note Purchase Agreement, Purchase Price Percentage, Exercise of Put Option, Greater than Total Funded Amount Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Moda Agreement Moda Agreement [Member] Moda Agreement Derivative Instrument [Axis] Derivative Instrument [Axis] Percentage of price option exercised Note Purchase Agreement, Purchase Price Percentage, Total Funded Amount, Exercise of Put Option Note Purchase Agreement, Exercise of Put Option, Purchase Price Percentage, Total Funded Amount Exercise Price Award Exercise Price Total liabilities Financial Liabilities Fair Value Disclosure Net Loss Per Share Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Subsequent event Subsequent Event [Member] Purchase Agreement, Knopp Amendment Purchase Agreement, Knopp Amendment [Member] Purchase Agreement, Knopp Amendment Shareholders' Equity: Equity, Attributable to Parent [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Fair Value, unrealized loss position less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Aggregate purchase price Note Purchase Agreement, Aggregate Purchase Price Note Purchase Agreement, Aggregate Purchase Price Segments [Domain] Segments [Domain] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Percentage of price option exercised, repurchased after closing date Note Purchase Agreement, Purchase Price Percentage, Repurchased Prior to the End of Voluntary Repurchase Period Percentage Of Price Option Exercised, Repurchased After Closing Date BHV-7000 & BHV-7010 (Kv7) BHV-7000 & BHV-7010 (Kv7) [Member] BHV-7000 & BHV-7010 (Kv7) All Individuals All Individuals [Member] Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] PEO PEO [Member] BHV-8000 (TYK2/JAK1) BHV-8000 (TYK2/JAK1) [Member] BHV-8000 (TYK2/JAK1) Name Trading Arrangement, Individual Name Non-operating (income) expense Other Nonoperating Income (Expense) Intangible assets Intangible Assets, Net (Excluding Goodwill) Percentage of revenue payment payable on quarterly basis Note Purchase Agreement, Maximum Percentage of Revenue Payments on Net Sales for Unsatisfied Test Date Condition Note Purchase Agreement, Maximum Percentage of Revenue Payments on Net Sales for Unsatisfied Test Date Condition Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Additional regulatory milestone payments Additional Success-Based Milestone Payments to be Paid, Based On Regulatory Approval Additional Success-Based Milestone Payments to be Paid, Based On Regulatory Approval Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Change in fair value of forward contract and derivative liabilities Increase (Decrease) in Fair Value of Derivative Liabilities Increase (Decrease) in Fair Value of Derivative Liabilities Third Notes Third Notes [Member] Third Notes Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Assets: Assets, Fair Value Disclosure [Abstract] 2024 Additional Consideration True-up 2024 Additional Consideration True-up [Member] 2024 Additional Consideration True-up Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Volatility (annual) Measurement Input, Price Volatility [Member] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Upfront payment of common shares, shares (in shares) Acquisition, Consideration Transferred, Equity Interest Issued and Issuable, Shares Acquisition, Consideration Transferred, Equity Interest Issued and Issuable, Shares Related Party [Domain] Related and Nonrelated Parties [Domain] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Common shares issuable, value Forward Contract, Obligation for Stock Issueable, Value Forward Contract, Obligation for Stock Issueable, Value Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Liability Class [Axis] Liability Class [Axis] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Direct R&D program expense Research And Development, Program Expense Research And Development, Program Expense FGFR3 Agreement, GeneQuantum Healthcare (Suzhou) Co. Ltd. and Aimed Bio, Inc. FGFR3 Agreement, GeneQuantum Healthcare (Suzhou) Co. Ltd. and Aimed Bio, Inc. [Member] FGFR3 Agreement, GeneQuantum Healthcare (Suzhou) Co. Ltd. and Aimed Bio, Inc. Schedule of RSU activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Requisite service period of award (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Changes in operating assets and liabilities, net of effects of acquisition: Increase (Decrease) in Operating Capital [Abstract] Allowance for Credit Losses Debt Securities, Available-for-Sale, Allowance for Credit Loss PEO Total Compensation Amount PEO Total Compensation Amount Roll forward of aggregate fair value determined by Level 3 inputs Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Schedule of accrued expenses and other current liabilities Schedule of Accrued Liabilities [Table Text Block] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Options vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Fair value first anniversary of execution period Obligation for Stock Issuable, Private Placement Period Obligation for Stock Issuable, Private Placement Period Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Common Shares Common Stock [Member] Measure: Measure [Axis] Net Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Rolling Maturity [Abstract] Common shares issuable (in shares) Developmental Milestone, Equity Interest Issuable, Shares Developmental Milestone, Equity Interest Issuable, Shares Issuance of common shares under 2022 Equity Incentive Plan Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Asset Class [Domain] Asset Class [Domain] Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Common stock issued (shares) Stock Issued During Period, Shares, New Issues Schedule of aggregate fair value of liability determined by Level 3 inputs Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Investments in continuous unrealized loss position for more than twelve months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions Entity Emerging Growth Company Entity Emerging Growth Company Segment Reporting [Abstract] Equity distribution agreement aggregate amount Equity Distribution Agreement, Maximum Aggregate Available, Amount Equity Distribution Agreement, Maximum Aggregate Available, Amount Entity Central Index Key Entity Central Index Key Other segment items Segment Reporting, Other Segment Item, Amount Second Asset Second Asset [Member] Second Asset General and administrative expenses General and Administrative Expense [Member] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Foreign currency translation adjustments: Accumulated Foreign Currency Adjustment Attributable to Parent [Member] U.S. treasury bonds US Treasury Bond Securities [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Shareholders' Equity Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Segment Information Segment Reporting Disclosure [Text Block] Building and land Land and Building [Member] Research and Development Arrangement Research and Development Arrangement [Member] Depreciable Property, Plant and Equipment Depreciable Property, Plant and Equipment [Member] Depreciable Property, Plant and Equipment Change in fair value of forward contract and derivative liabilities in other income, net Change in fair value of forward contract and derivative liabilities in other income, net Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Adjustments to reconcile net loss to net cash used in operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Funded loan amount on, test date condition not satisfied but greater than total funded percentage amount Note Purchase Agreement, Cap Amount Multiplier, Unsatisfied Test Date Condition, Greater than Total Funded Amount Percentage Note Purchase Agreement, Cap Amount Multiplier, Unsatisfied Test Date Condition, Greater than Total Funded Amount Percentage Non-cash share-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Moda Pharmaceuticals LLC Moda Pharmaceuticals LLC [Member] Moda Pharmaceuticals LLC Repurchased after first anniversary but prior to second anniversary Note Purchase Agreement, Purchase Price Percentage, Total Funded Amount, Exercise of Put Option, Repurchased After First Anniversary but Prior to Second Anniversary Note Purchase Agreement, Purchase Price Percentage, Total Funded Amount, Exercise of Put Option, Repurchased After First Anniversary but Prior to Second Anniversary Title Trading Arrangement, Individual Title Statement [Table] Statement [Table] 2025 Additional Consideration True-up 2025 Additional Consideration True-up [Member] 2025 Additional Consideration True-up Counterparty Name [Axis] Counterparty Name [Axis] Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Consolidation Items [Domain] Consolidation Items [Domain] Numerator: Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Research and development accrual Upfront Payments, Cash Payments, Research and Development Accrual Upfront Payments, Cash Payments, Research and Development Accrual Pyramid Biosciences, Inc. Pyramid Biosciences, Inc. [Member] Pyramid Biosciences, Inc. Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Accrued clinical trial costs Accrued Clinical Trial Costs, Current Amount of expenses incurred but not yet paid classified as clinical trial costs, due within one year or the normal operating cycle, if longer. Available-for-sale Securities, Debt Maturities [Abstract] Available-for-Sale Securities, Debt Maturities [Abstract] Acquisition [Axis] Acquisition [Axis] Acquisition Net Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss BMS BMS [Member] BMS Options exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number BHV-2100 (TRPM3 Antagonist) BHV-2100 (TRPM3 Antagonist) [Member] BHV-2100 (TRPM3 Antagonist) Minimum annual royalty payment to be paid upon sale of product Minimum Annual Royalty Payment To Be Paid By Company Upon Sale Of Product Minimum Annual Royalty Payment To Be Paid By Company Upon Sale Of Product Restricted cash (included in other current assets) Restricted Cash Included in Other Current Assets Restricted Cash Included in Other Current Assets Schedule of net investment income Investment Income [Table Text Block] Weighted Average Contractual Term and Aggregate Intrinsic Value Share-Based Awards, Weighted Average Contractual Term And Aggregate Intrinsic Value [Abstract] Share-Based Awards, Weighted Average Contractual Term And Aggregate Intrinsic Value Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Schedule of fair value measurement inputs and valuation techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Time to payment and potential payment (years) Measurement Input, Expected Term [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Equity [Abstract] Debt securities (including realized losses) Interest Income, Debt Securities, Operating Accumulated deficit Retained Earnings (Accumulated Deficit) Related Party Transactions Related Party Transaction [Line Items] General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Marketable securities Marketable Securities, Current [Member] Marketable Securities, Current Other investments Interest Income, Other Amendment Flag Amendment Flag Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table] Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table] Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Number of Securities, unrealized loss position less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions Depreciation and amortization Depreciation, Depletion and Amortization Issuance of common shares as payment under license and other agreements Stock Issued During Period, Value, Collaborative Arrangement Stock Issued During Period, Value, Collaborative Arrangement Fair Value as of Grant Date Award Grant Date Fair Value Subsequent Events [Abstract] Obligation to issue common shares as payment under license and other agreements (in shares) Obligation to Issue Stock, Shares, Obligation Arrangement Obligation to Issue Stock, Shares, Obligation Arrangement Level 2 Fair Value, Inputs, Level 2 [Member] Forward contract and derivative liability Forward Contract, Current Forward Contract, Current Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Other R&D program expense Other R&D Program Expense [Member] Other R&D Program Expense Initial term of agreement (in years) Agreement, Initial Term Agreement, Initial Term Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Upfront payment of common shares, shares issued (in shares) Acquisition, Consideration Transferred, Equity Interest Issued, Shares Acquisition, Consideration Transferred, Equity Interest Issued, Shares Issuance of common shares, net of offering costs Stock Issued During Period, Value, New Issues 2023 Yale SRA 2023 Yale Sponsored Research Agreement [Member] 2023 Yale Sponsored Research Agreement Entity Address, Postal Zip Code Entity Address, Postal Zip Code Type of Arrangement and Non-arrangement Transactions [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of non-cash share-based compensation expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Title of 12(b) Security Title of 12(b) Security Common shares, no par value; 200,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 102,104,024 and 101,221,989 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively Common Stock, Value, Issued Share-Based Payment Arrangement [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Funded loan amount on test date condition satisfaction Note Purchase Agreement, Cap Amount Multiplier, Satisfied Test Date Condition Note Purchase Agreement, Cap Amount Multiplier, Satisfied Test Date Condition BHV-1400 (IgA Degrader) BHV-1400 (IgA Degrader) [Member] BHV-1400 (IgA Degrader) Issuance of common shares as payment under license and other agreements Proceeds from Issuance of Common Stock for License Agreements Proceeds from Issuance of Common Stock for License Agreements Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Aggregate intrinsic value of options vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Accrued Expense and Other Current Liabilities Accrued Liabilities, Current [Abstract] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Common shares issued (in shares) Developmental Milestone, Equity Interest Issued, Shares Developmental Milestone, Equity Interest Issued, Shares Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Preferred shares, no par value; 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2025 and December 31, 2024 Preferred Stock, Value, Issued First and Third Notes First and Third Notes [Member] First and Third Notes Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Forward contract, current Forward Contracts [Member] Net loss per share — basic (in dollars per share) Net loss per share - basic (in dollars per share) Earnings Per Share, Basic Accounts payable Increase (Decrease) in Accounts Payable Cash acquired from acquisition of IPR&D asset Cash Acquired from Acquisition Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Share-based award term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Yale Arrangement Yale Collaborative Arrangement [Member] Yale Collaborative Arrangement Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Summary of debt securities available-for-sale in an unrealized loss position, aggregated by the length of time Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Total assets Assets Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Other non-current liabilities Other Liabilities, Noncurrent Unvested options expected to vest (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Nonvested Expected To Vest, Number of Shares Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Nonvested Expected To Vest, Number of Shares G&A personnel expense (excluding share-based compensation) General And Administrative Expense, Personnel Expense, Excluding Share-Based Compensation General And Administrative Expense, Personnel Expense, Excluding Share-Based Compensation Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies (Note 11) Commitments and Contingencies Termination Date Trading Arrangement Termination Date Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Table] Exercise price of warrants (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Fair Value, Assets and Liabilities Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Non-Cash Share-Based Compensation Share-Based Payment Arrangement [Text Block] Purchase Agreement, Knopp Amendment, 2025 Additional Consideration Purchase Agreement, Knopp Amendment, 2025 Additional Consideration [Member] Purchase Agreement, Knopp Amendment, 2025 Additional Consideration Entity Address, City or Town Entity Address, City or Town Debt Instrument [Axis] Debt Instrument [Axis] Schedule of stock option activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Net loss Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Investments, Debt and Equity Securities [Abstract] Other Commitments [Table] Other Commitments [Table] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Voluntary repurchase, period Note Purchase Agreement, Voluntary Repurchase Period Note Purchase Agreement, Voluntary Repurchase Period Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Fair Value to Amortized Cost Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract] Entity File Number Entity File Number Funded loan amount, after anniversary of closing date Note Purchase Agreement, Cap Amount Multiplier, Unsatisfied Test Date Condition, Less than Total Funded Amount Percentage After Eighth Anniversary of Closing Date Note Purchase Agreement, Cap Amount Multiplier, Unsatisfied Test Date Condition, Less than Total Funded Amount Percentage After Eighth Anniversary of Closing Date Liabilities: Liabilities, Fair Value Disclosure [Abstract] Test date condition, satisfaction rate on total payments, equal to or greater than 50% Note Purchase Agreement, Unsatisfied Test Date Condition, Total Funded Amount Threshold Percentage Note Purchase Agreement, Unsatisfied Test Date Condition, Total Funded Amount Threshold Percentage Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Funded loan amount, on or prior to anniversary of closing date Note Purchase Agreement, Cap Amount Multiplier, Unsatisfied Test Date Condition, Less than Total Funded Amount Percentage Prior to Eighth Anniversary of Closing Date Note Purchase Agreement, Cap Amount Multiplier, Unsatisfied Test Date Condition, Less than Total Funded Amount Percentage Prior to Eighth Anniversary of Closing Date Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Entity Address, Address Line Two Entity Address, Address Line Two Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] BHV-2000 (Taldefgrobep Alfa) BHV-2000 (Taldefgrobep Alfa) [Member] BHV-2000 (Taldefgrobep Alfa) Effects of exchange rates on cash, cash equivalents, and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Other accrued expenses and other current liabilities Other Accrued Liabilities, Current Total assets Assets, Fair Value Disclosure Accrued expenses and other current and non-current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Name Forgone Recovery, Individual Name Aggregate intrinsic value of options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Forward Contract Liability, 2024 Additional Consideration Forward Contract Liability, 2024 Additional Consideration [Member] Forward Contract Liability, 2024 Additional Consideration Second Notes Second Notes [Member] Second Notes Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Written put option, current Put Option [Member] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Other non-cash items, net Other Noncash Income (Expense) Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Unvested, beginning (in shares) Unvested, ending (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Asset Class [Axis] Asset Class [Axis] Insider Trading Arrangements [Line Items] Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Adjustment to Compensation: Adjustment to Compensation [Axis] R&D personnel expense (excluding share-based compensation) Research And Development Expense, Personnel Expenses, Excluding Share-Based Compensation Research And Development Expense, Personnel Expenses, Excluding Share-Based Compensation Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items] Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items] Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Obligation to issue common shares as payment under license and other agreements Obligation to Issue Stock, Value, Obligation Arrangement Obligation to Issue Stock, Value, Obligation Arrangement Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Fair Value Debt Securities, Available-for-Sale, Maturity, Fair Value, Rolling Maturity [Abstract] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Related Party [Axis] Related and Nonrelated Parties [Axis] Weighted average common shares outstanding—basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Funded loan amount Note Purchase Agreement, Cap Amount Multiplier Note Purchase Agreement, Cap Amount Multiplier Repurchased after second anniversary Note Purchase Agreement, Purchase Price Percentage, Total Funded Amount, Exercise of Put Option, Repurchased After Second Anniversary Note Purchase Agreement, Purchase Price Percentage, Total Funded Amount, Exercise of Put Option, Repurchased After Second Anniversary BHV-1530 (FGFR3) BHV-1530 (FGFR3) [Member] BHV-1530 (FGFR3) Nature of business [Line Items] Subsidiary, Sale of Stock [Line Items] Restricted share units Restricted Stock Units (RSUs) [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Equipment not yet in service Construction in Progress [Member] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Unrealized Losses, unrealized loss position less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Entity Filer Category Entity Filer Category Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-Sale Company Selected Measure Name Company Selected Measure Name